4.07

0.25% 0.01

After Hours: 4.10 0.03 +0.74%

Opus Genetics Inc (IRD)

Overview News Price History Discussions Forecast

Opus Genetics Inc stock is traded at $4.07, with a volume of 1.06M. It is up +0.25% in the last 24 hours and down -8.33% over the past month. Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes seven adeno-associated virus (AAV)-based programs, led by OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration, with additional candidates targeting RHO, CNGB1, RDH12, NMNAT1, and MERTK. The company operates in one operating segment, which is the business of developing products related to vision performance and health.

Previous Close:

$4.06

Open:

$4.17

24h Volume:

1.06M

Relative Volume:

1.30

Market Cap:

$336.04M

Revenue:

$14.20M

Net Income/Loss:

$-49.59M

P/E Ratio:

-4.8314

EPS:

-0.8424

Net Cash Flow:

$-35.25M

1W Performance:

+4.09%

1M Performance:

-8.33%

6M Performance:

+105.56%

1Y Performance:

+337.02%

1-Day Range:

$4.035

$4.26

1-Week Range:

$3.80

$4.26

52-Week Range:

$0.9011

$5.81

Opus Genetics Inc Stock (IRD) Company Profile

Name

Opus Genetics Inc

Sector

Healthcare (1104)

Industry

Biotechnology (617)

Phone

248-681-9815

Address

8 DAVIS DRIVE, DURHAM

Employee

Twitter

Next Earnings Date

2026-08-12

Latest SEC Filings

IRD's Discussions on Twitter

Compare IRD vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
IRD Opus Genetics Inc	4.07	335.22M	14.20M	-49.59M	-35.25M	-0.8424
VRTX Vertex Pharmaceuticals Inc	451.63	116.49B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	609.94	63.73B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	877.72	55.49B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	278.09	37.75B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	162.99	33.54B	742.00K	-1.37B	-1.07B	-7.0731

Opus Genetics Inc Stock (IRD) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-30-26	Initiated	Cantor Fitzgerald	Overweight
Mar-16-26	Initiated	Oppenheimer	Outperform
Jan-20-26	Initiated	BTIG Research	Buy
Dec-10-25	Initiated	B. Riley Securities	Buy
Nov-25-25	Initiated	Piper Sandler	Overweight
Oct-29-25	Initiated	Wedbush	Outperform
Oct-16-25	Initiated	Chardan Capital Markets	Buy
Apr-11-25	Initiated	Craig Hallum	Buy
Nov-13-24	Resumed	H.C. Wainwright	Buy

View All

Opus Genetics Inc Stock (IRD) Latest News

Jun 18, 2026

A Quick Look at Today's Ratings for Opus Genetics(IRD.US), With a Forecast Between $8 to $13 - Moomoo

Jun 18, 2026

IRD Maintained by Chardan Capital -- Price Target Raised to $13. - GuruFocus

Jun 18, 2026

Chardan Raises Price Target on Opus Genetics to $13 From $11, Keeps Buy Rating - marketscreener.com

Jun 18, 2026

Opus Genetics, Inc. Stock 12‑Month Price Target Raised to $10.69, Implies 163% Upside - TradingView

Jun 18, 2026

Jun 17, 2026

Chardan Capital Maintains Opus Genetics(IRD.US) With Buy Rating, Raises Target Price to $13 - Moomoo

Jun 17, 2026

symbol__ Stock Quote Price and Forecast - CNN

Jun 17, 2026

IRD Reiterated by HC Wainwright & Co. -- Price Target Maintained at $8.00 - GuruFocus

Jun 17, 2026